Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probiotic K10
- Development stage
- Unknown
- Lead developer
- Micillic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probiotic K10 is a probiotic mixture (referred to as the 'K10 probiotic mix') being investigated as a potential treatment for neurodegenerative diseases, specifically Parkinson's disease and Alzheimer's disease. Developed by Micillic Ltd, it is categorized as a microbial therapy or live biotherapeutic product. The drug has been evaluated in a single-centre, double-blind, placebo-controlled, randomized Phase III clinical trial (NCT06019117) in Brazil, focusing on cognitive, motor, and psychiatric neurological outcomes. The trial included patients with Parkinson's disease and those in the early stages of Alzheimer's disease, ranging from mild cognitive impairment to mild dementia. While the specific bacterial strains and precise biological targets are not publicly disclosed, the therapy aims to leverage the gut-brain axis to manage health outcomes in these populations.
- Brand names
- probiotic k10
- Other names
- K10 probioticK-10 probioticK 10 probioticK10 probiotic mixK-10 probiotic mixK 10 probiotic mixProbiotic K10
Beyond the preview
Go deeper on Probiotic K10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probiotic K10.